ImageneBio, Inc. - Asset Resilience Ratio
ImageneBio, Inc. (IMA) has an Asset Resilience Ratio of 27.28% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of ImageneBio, Inc. to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how ImageneBio, Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see IMA total assets.
Liquid Assets Composition Over Time
This chart breaks down ImageneBio, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore IMA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $41.48 Million | 27.28% |
| Total Liquid Assets | $41.48 Million | 27.28% |
Asset Resilience Insights
- Very High Liquidity: ImageneBio, Inc. maintains exceptional liquid asset reserves at 27.28% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ImageneBio, Inc. Industry Peers by Asset Resilience Ratio
Compare ImageneBio, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for ImageneBio, Inc. (2022–2025)
The table below shows the annual Asset Resilience Ratio data for ImageneBio, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 26.68% | $40.82 Million | $152.98 Million | -33.38pp |
| 2024-12-31 | 60.06% | $84.99 Million | $141.51 Million | +31.13pp |
| 2023-12-31 | 28.93% | $55.57 Million | $192.09 Million | -27.40pp |
| 2022-12-31 | 56.33% | $97.03 Million | $172.26 Million | -- |
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerl… Read more